Imperial College Kidney and Transplant Institute, West London Renal and Transplant Centre, Imperial College Healthcare Trust, Hammersmith Hospital, DuCane Road, London W12 0HS, UK.
Nephrol Dial Transplant. 2010 May;25(5):1588-95. doi: 10.1093/ndt/gfp683. Epub 2009 Dec 18.
Vascular access for haemodialysis is achieved by tunnelled central venous catheter (CVC) in at least 23% of prevalent patients in the UK, Canada and the USA. Use of CVCs is associated with an increased incidence of venous stenosis that can progressively limit future vascular access routes. Lack of conventional venous access routes mandates the use of alternative strategies such as the translumbar approach.
We retrospectively analysed patients at our centre requiring translumbar inferior vena caval CVCs (TesioCath) for haemodialysis in the period 1999-2008. Written and electronic records capturing dialysis adequacy and complications, hospital admissions and laboratory data were examined.
Thirty-nine pairs of translumbar CVCs were inserted in 26 patients with 15 864 catheter days follow-up, mean patient age 61.9 +/- 12.1 years, 31% diabetic, 15% with ischaemic heart disease. All insertions were successful. Insertion of one CVC was associated with a self-limiting retroperitoneal haematoma. No patients died of a catheter-related cause or through lack of vascular access. Cumulative assisted primary catheter site patency was 81% at 6 months and 73% at 1 year (median 18.5 months). Good dialysis adequacy was achieved throughout (mean single-pool Kt/V 1.5 +/- 0.4). The incidence of access-related infection was 2.84/1000 catheter days (exit site infection rate 2.02/1000 catheter days; catheter-related bacteraemia rate 0.82/1000 catheter days). Catheter dysfunction (need for thrombolytic infusion or catheter change) led to 0.88 admissions per 1000 catheter days.
Translumbar inferior vena caval CVCs can offer relatively safe and effective long-term haemodialysis access in patients with no other options.
在英国、加拿大和美国,至少有 23%的现患患者通过隧道式中心静脉导管(CVC)进行血液透析。CVC 的使用与静脉狭窄的发生率增加有关,静脉狭窄可逐渐限制未来的血管通路。缺乏常规静脉通路需要采用替代策略,如经皮穿刺入路。
我们回顾性分析了 1999 年至 2008 年期间在我们中心因血液透析而需要经皮穿刺入路下腔静脉 TesioCath 导管的患者。检查了记录透析充分性和并发症、住院和实验室数据的书面和电子记录。
26 例患者共插入 39 对经皮穿刺入路下腔静脉 CVC,随访 15864 导管日,患者平均年龄为 61.9+/-12.1 岁,31%为糖尿病患者,15%为缺血性心脏病患者。所有插入均成功。一次插入与自限性腹膜后血肿相关。没有患者因导管相关原因或血管通路不足而死亡。辅助原发性导管部位通畅率 6 个月时为 81%,1 年时为 73%(中位数 18.5 个月)。整个过程中均实现了良好的透析充分性(平均单池 Kt/V 为 1.5+/-0.4)。与通路相关的感染发生率为 2.84/1000 导管日(出口部位感染率为 2.02/1000 导管日;导管相关菌血症率为 0.82/1000 导管日)。导管功能障碍(需要溶栓输注或更换导管)导致每 1000 导管日有 0.88 次住院。
在没有其他选择的情况下,经皮穿刺入路下腔静脉 CVC 可为患者提供相对安全有效的长期血液透析通路。